secwatch.observer — SEC 8-K summary
======================================

Issuer:     QUEST DIAGNOSTICS INC (DGX)
CIK:        0001022079
Form:       8-K
Filed at:   2025-10-21T23:59:59+00:00
Accession:  0001022079-25-000219
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quest Diagnostics Q3 revenue $2.82B (+13.1%), raises FY2025 adjusted EPS guidance to $9.76–$9.84
--------------------------------------------------------------------------------

- Q3 reported diluted EPS $2.16 (+8.5%); adjusted diluted EPS $2.60 (+13.0%) vs $2.30 prior year.
- Revenue up 13.1% to $2.82B with 6.8% organic growth; diagnostic info services revenue $2.76B.
- FY2025 adjusted EPS guidance raised to $9.76–$9.84 from $9.63–$9.83; revenue guidance raised to $10.96B–$11.00B.
- Year-to-date cash from operations $1.42B, up 63.1%; Co-Lab Solutions annual revenue run-rate ~$1B expected next year.
- Announced lab services JV with Corewell Health; acquired dialysis testing assets from Fresenius Medical Care.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1022079/000102207925000219/0001022079-25-000219-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1022079/000102207925000219/dgx-20251021.htm
  HTML page:      https://secwatch.observer/filing/0001022079-25-000219

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer